Growth Metrics

Tango Therapeutics (TNGX) Shares Outstanding (Diluted Average) (2021 - 2025)

Tango Therapeutics has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $116.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $116.2 million for Q4 2025, up 6.35% from a year ago — trailing twelve months through Dec 2025 was $116.2 million (up 6.35% YoY), and the annual figure for FY2025 was $116.2 million, up 6.35%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $116.2 million at Tango Therapeutics, up from $110.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TNGX hit a ceiling of $116.2 million in Q4 2025 and a floor of $48.5 million in Q2 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $91.4 million (2023), compared with a mean of $92.9 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 80.89% in 2022 and later rose 0.58% in 2023.
  • Tango Therapeutics' Shares Outstanding (Diluted Average) stood at $62.1 million in 2021, then skyrocketed by 41.4% to $87.8 million in 2022, then rose by 7.69% to $94.6 million in 2023, then increased by 15.5% to $109.2 million in 2024, then increased by 6.35% to $116.2 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $116.2 million (Q4 2025), $110.5 million (Q2 2025), and $110.3 million (Q1 2025) per Business Quant data.